Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
David A. Reardon(Dana-Farber Cancer Institute), Zariana Nikolova(Bristol-Myers Squibb (Switzerland)), Martin J. van den Bent(Erasmus MC Cancer Institute), Sophie Taillibert(Sorbonne Université), Henrik Schultz(Aarhus University Hospital), Alexander Weir(Novartis (Switzerland)), Jacob C. Easaw(Alberta Health Services), Peter Hau(University Hospital Regensburg), Uwe Schlegel(Defence Research and Development Organisation), G. Dresemann, S. Green(Novartis (Switzerland)), Mario Campone(Institut de Cancérologie de l'Ouest), Laurence Gordower(Université Libre de Bruxelles), Jeffrey Raizer(Northwestern University), Per Bergström, Erik Blomquist(Uppsala University Hospital), Paul M. Clément(Universitair Ziekenhuis Leuven), J.-C. Tonn(LMU Klinikum), Anja Gijtenbeek(Radboud University Nijmegen)
Cited by 130
Related Papers
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
|Nature|2018|1.5k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k